The Latin America, Middle East and Africa Bispecific Antibodies Market should witness market growth of 50.3% CAGR during the forecast period (2023-2030).
Bispecific antibodies are becoming increasingly in demand, and as more international pharmaceutical companies enter the market, so does competition amongst businesses to stay ahead of the competition. Numerous of these businesses are investing in the creation of innovative bispecific antibody forms that are anticipated to have improved efficacy, stability, and specificity. It is anticipated that this investment in R&D would spur innovation in the domain of bispecific antibodies, ultimately leading to the introduction of brand-new, cutting-edge medicines.
According to the National Library of Medicine, over 100 BsAbs were under clinical evaluation in 2022. These were being evaluated for their efficacy in cancer treatment. Antibody engineers have been motivated to increase the effectiveness of these molecules by the clinical and financial triumphs achieved by rituximab, trastuzumab, cetuximab, and other mAbs. Thus, a new wave of antibodies with modified Fc resulting in considerably stronger effector capabilities, like complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity, is being tested in the clinic, and numerous approvals are anticipated soon. Bispecific antibodies can help by targeting two separate disease mediators concurrently, rerouting T-cells to tumor cells, inhibiting 2 different signaling pathways at the same time, as well as delivering payloads to targeted areas due to their dual specificity.
The prevalence of cancer is increasing in LAMEA. It was projected that each year in Latin America, 1.5 million new instances of cancer and 700,000 cancer deaths occur. Incidence and death rates were correspondingly 186.5 and 86.6 per 100 000 (age-standardized). Prostate cancer accounted for 15% of all new instances of cancer in Latin America and the Caribbean in 2020, followed by breast cancer, colorectal cancer, lung cancer, and stomach cancer, excluding non-melanoma skin cancers. Even though rates varied greatly between nations, lung cancer remained the major cause of cancer death (12% of all cancer fatalities). Consequently, the region offers the market substantial potential opportunities.
The Brazil market dominated the LAMEA Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,456.6 million by 2030. The Argentina market is estimated to grow at a CAGR of 51.2% during (2023-2030). Additionally, The UAE market would register a CAGR of 49.9% during (2023-2030).
Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).
Bispecific antibodies are becoming increasingly in demand, and as more international pharmaceutical companies enter the market, so does competition amongst businesses to stay ahead of the competition. Numerous of these businesses are investing in the creation of innovative bispecific antibody forms that are anticipated to have improved efficacy, stability, and specificity. It is anticipated that this investment in R&D would spur innovation in the domain of bispecific antibodies, ultimately leading to the introduction of brand-new, cutting-edge medicines.
According to the National Library of Medicine, over 100 BsAbs were under clinical evaluation in 2022. These were being evaluated for their efficacy in cancer treatment. Antibody engineers have been motivated to increase the effectiveness of these molecules by the clinical and financial triumphs achieved by rituximab, trastuzumab, cetuximab, and other mAbs. Thus, a new wave of antibodies with modified Fc resulting in considerably stronger effector capabilities, like complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity, is being tested in the clinic, and numerous approvals are anticipated soon. Bispecific antibodies can help by targeting two separate disease mediators concurrently, rerouting T-cells to tumor cells, inhibiting 2 different signaling pathways at the same time, as well as delivering payloads to targeted areas due to their dual specificity.
The prevalence of cancer is increasing in LAMEA. It was projected that each year in Latin America, 1.5 million new instances of cancer and 700,000 cancer deaths occur. Incidence and death rates were correspondingly 186.5 and 86.6 per 100 000 (age-standardized). Prostate cancer accounted for 15% of all new instances of cancer in Latin America and the Caribbean in 2020, followed by breast cancer, colorectal cancer, lung cancer, and stomach cancer, excluding non-melanoma skin cancers. Even though rates varied greatly between nations, lung cancer remained the major cause of cancer death (12% of all cancer fatalities). Consequently, the region offers the market substantial potential opportunities.
The Brazil market dominated the LAMEA Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,456.6 million by 2030. The Argentina market is estimated to grow at a CAGR of 51.2% during (2023-2030). Additionally, The UAE market would register a CAGR of 49.9% during (2023-2030).
Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).
Scope of the Study
By Indication
- Cancer
- Inflammatory & Autoimmune Disorder
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Akeso, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Taisho Pharmaceuticals Holding Co., Ltd.
- Immunocore Holdings plc
- GlaxoSmithKline PLC (GSK)
- Novartis AG
- Allergan PLC (AbbVie, Inc.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Bispecific Antibodies Market by Indication
Chapter 5. LAMEA Bispecific Antibodies Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Akeso, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Taisho Pharmaceuticals Holding Co., Ltd.
- Immunocore Holdings plc
- GlaxoSmithKline PLC (GSK)
- Novartis AG
- Allergan PLC (AbbVie, Inc.)
Methodology
LOADING...
